Comerica Securities Inc. Buys 8,181 Shares of Amgen Inc. (AMGN)
Comerica Securities Inc. raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 184.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,608 shares of the medical research company’s stock after buying an additional 8,181 shares during the period. Comerica Securities Inc.’s holdings in Amgen were worth $2,069,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in the stock. Camelot Portfolios LLC purchased a new position in Amgen during the first quarter worth about $1,429,000. Private Asset Management Inc. increased its position in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares in the last quarter. Cadence Bank NA increased its position in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares in the last quarter. Stillwater Capital Advisors LLC purchased a new position in Amgen during the first quarter worth about $202,000. Finally, Kornitzer Capital Management Inc. KS increased its position in Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock worth $6,377,000 after buying an additional 16,080 shares in the last quarter. Institutional investors and hedge funds own 79.12% of the company’s stock.
Amgen Inc. (AMGN) opened at 167.29 on Friday. The stock’s 50 day moving average price is $174.04 and its 200-day moving average price is $168.05. The stock has a market capitalization of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $2.84 earnings per share. On average, equities analysts expect that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is 41.93%.
AMGN has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Finally, Argus upped their price objective on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen has an average rating of “Buy” and a consensus price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.